Antibody responses to GalC in severe and complicated childhood Guillain-Barré syndrome by Meyer Sauteur, Patrick M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Antibody responses to GalC in severe and complicated childhood
Guillain-Barré syndrome
Meyer Sauteur, Patrick M; Huizinga, Ruth; Tio-Gillen, Anne P; de Wit, Marie-Claire Y; Unger, Wendy
W J; Berger, Christoph; van Rossum, Annemarie M C; Jacobs, Bart C
Abstract: We recently presented a case series of seven children who developed severe and complicated
Guillain-Barré syndrome (GBS) after infection with M. pneumoniae (Mp) (Meyer Sauteur et al., 2015).
The disease was rapidly progressive and severe: one died, four had clinically defined central nervous
system (CNS) involvement, and five required mechanical ventilation.
DOI: https://doi.org/10.1111/jns.12243
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-142694
Journal Article
Accepted Version
Originally published at:
Meyer Sauteur, Patrick M; Huizinga, Ruth; Tio-Gillen, Anne P; de Wit, Marie-Claire Y; Unger, Wendy
W J; Berger, Christoph; van Rossum, Annemarie M C; Jacobs, Bart C (2018). Antibody responses to
GalC in severe and complicated childhood Guillain-Barré syndrome. Journal of the Peripheral Nervous
System, 23(1):67-69.
DOI: https://doi.org/10.1111/jns.12243
A
cc
ep
te
d 
A
rti
cl
e
Antibody responses to GalC in severe and complicated childhood Guillain-
Barré syndrome 
 
Patrick M. Meyer Sauteur1,2*, Ruth Huizinga3, Anne P. Tio-Gillen3,4, Marie-Claire Y. 
de Wit5, Wendy W.J. Unger1, Christoph Berger2, Annemarie M.C. van Rossum1, Bart 
C. Jacobs3,4 
 
1 Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC–
Sophia Children’s Hospital, University Medical Center, Rotterdam, The Netherlands 
2 Division of Infectious Diseases and Hospital Epidemiology, University Children’s Hospital Zurich, 
Zurich, Switzerland 
3 Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 
4 Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands 
5 Department of Pediatrics, Division of Pediatric Neurology, Erasmus MC–Sophia Children’s 
Hospital, University Medical Center, Rotterdam, The Netherlands 
 
Running headline: 
Anti-GalC antibodies in severe and complicated M. pneumoniae-associated 
childhood GBS 
 
Corresponding author: 
Patrick Meyer Sauteur, MD 
Division of Infectious Diseases and Hospital Epidemiology, University Children’s 
Hospital Zurich, Steinwiesstrasse 75 
CH-8032 Zurich, Switzerland 
T: +41 44 266 78 96 
F: +41 44 266 80 72 
E: patrick.meyer@kispi.uzh.ch 
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1111/jns.12243 
  
A
cc
ep
te
d 
A
rti
cl
e
 
Key words 
Central nervous system; children; galactocerebroside; Guillain-Barré syndrome; 
Mycoplasma pneumoniae 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Dear Editor, 
We recently presented a case series of seven children who developed severe and 
complicated Guillain-Barré syndrome (GBS) after infection with M. pneumoniae (Mp) 
(Meyer Sauteur et al., 2015). The disease was rapidly progressive and severe: one 
died, four had clinically defined central nervous system (CNS) involvement, and five 
required mechanical ventilation. Given the often relatively benign disease course of 
GBS after this specific type of infection (Meyer Sauteur et al., 2016) the severe and 
complicated GBS in this series was rather unexpected. Since we recently 
demonstrated that pediatric and adult GBS after Mp infection is associated with 
antibodies against galactocerebroside (GalC) (Meyer Sauteur et al., 2016) we 
investigated if anti-GalC antibodies were also present in these children with severe 
GBS. 
 
Sera were tested for IgM and IgG antibodies to GM1, GM2, GD1a, GD1b, GQ1b, and 
GalC (all from Sigma-Aldrich, Zwijndrecht, the Netherlands) as previously described 
(Ang et al., 2000; Kuijf et al., 2005; Meyer Sauteur et al., 2016). CSF was tested for 
IgM and IgG to GalC at 1:10 dilution. ODs at 490 nm from uncoated wells (containing 
ethanol) were subtracted from glycolipid-coated wells. Cut-off values (0.05 for IgG 
and 0.03 for IgM) were obtained by measuring 14 CSF samples of patients with other 
neurological diseases (mean OD plus 3 times the standard deviation). Some patients 
had previously been included in other studies (Meyer Sauteur et al., 2016; Meyer 
Sauteur et al., 2014; Roodbol et al., 2014). 
Data were analyzed using the R software environment (version 3.4.1). The χ2 test 
was used to compare proportions. Two-sided p values <0.05 were considered to be 
statistically significant. The study was approved by the Erasmus MC Medical Ethics 
Board. 
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Anti-GalC IgG and/or IgM were found in six out of seven patients (86%). Antibodies 
against other glycolipids were present in three of those six (anti-GM1). No antibodies 
were found against complexes of two glycolipids (data not shown). 
Since anti-GalC IgG is specifically associated with GBS after Mp infection (Meyer 
Sauteur et al., 2016), we next compared the frequency of anti-GalC IgG in severe 
Mp-positive pediatric GBS to (1) Mp-positive pediatric GBS patients (cohort as 
previously described (Meyer Sauteur et al., 2016)), who did not fulfill the criteria for 
severe GBS (Meyer Sauteur et al., 2015) (defined as "less-severe" GBS), and (2) 
Mp-negative pediatric GBS (Meyer Sauteur et al., 2016). The presence of anti-GalC 
IgG was significantly more frequent in serum of severe Mp-positive GBS patients 
(43%, n=3/7) than in "less-severe" Mp-positive GBS (17%, n=2/12; p=0.04, Figure 1) 
or Mp-negative GBS (0%, n=0/8; p=0.03). 
Sufficient CSF was available in three patients with severe Mp-positive GBS. CSF 
anti-GalC IgG and IgM was found in three (100%) and one (33%), respectively. All 
these three did show signs and symptoms of CNS involvement. 
 
The increased presence of anti-GalC IgG in severe Mp-positive GBS compared to 
"less-severe" Mp-positive GBS may suggest that these antibodies are also involved 
in the development of severe and complicated GBS. Anti-GalC IgG was also 
detected in another recent study in GBS as most frequent anti-glycolipid antibody, 
identified in 37% (Kuwahara et al., 2017). The reason for the poor outcome in our 
series (one patient died and only two patients recovered completely) remains 
unclear. We (Meyer Sauteur et al., 2016) and Samukawa and coworkers (Samukawa 
et al., 2014) found previously no significant difference in the outcomes between anti-
GalC-positive and anti-GalC-negative GBS. In both studies, the anti-GalC-negative 
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group consisted of different subgroups of GBS patients including Campylobacter 
jejuni-related anti-GM1-positive patients who are known to have a poor outcome 
(Rees et al., 1995). Here, all comparisons were performed within the Mp-positive 
GBS group. Another risk factor for poor outcome in GBS is more severe disease at 
entry (van den Berg et al., 2013). The development of GBS may also depend on 
patient-related factors that influence the susceptibility to produce cross-reactive anti-
glycolipid antibodies triggered by infections (Huizinga et al., 2015). The differential 
outcome between severe Mp-positive GBS patients of our series and "less-severe" 
Mp-positive GBS may suggest that our patients were more prone to produce a 
stronger immune response causing GBS. Indeed, the titers of anti-GalC IgG in these 
patients were higher compared to "less-severe" Mp-positive GBS. Apart from the role 
of anti-GalC antibodies, also other host factors may account for distinct outcomes in 
GBS (Geleijns et al., 2006; van den Berg et al., 2014). 
Of the seven GBS patients in this series, four had CNS involvement (two were 
comatose). The relatively frequent CNS involvement in neurological diseases 
associated with Mp may be common in children. Kuwahara and coworkers 
(Kuwahara et al., 2017) observed that patients with CNS diseases were younger than 
those with GBS and variants, and hypothesized that this could possibly be a result of 
the relatively undeveloped blood-brain barrier in children. 
 
In conclusion, the correlation of anti-GalC IgG with a severe and complicated disease 
course and presence in CSF of patients with CNS involvement suggests that these 
antibodies may contribute to the pathogenesis of severe Mp-associated childhood 
GBS. 
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Figure Legends 
Figure 1. Anti-GalC isotype distribution in children with severe and "less-
severe" M. pneumoniae (Mp)-associated GBS. Serum anti-GalC antibodies were 
determined in severe Mp-positive childhood GBS of the case series (Meyer Sauteur 
et al., 2015) and compared to its presence in "less-severe" Mp-positive childhood 
GBS of our previous GBS case-control study (Meyer Sauteur et al., 2016). Mp+ 
indicates positive for anti-Mp IgM ± IgG (both isotypes have been associated with 
GBS (Meyer Sauteur et al., 2016)). Differences in proportions are indicated with the 
corresponding p value (χ2 test). Abbreviations: GalC, galactocerebroside; GBS, 
Guillain-Barré syndrome; Ig, immunoglobulin; Mp, M. pneumoniae. 
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